Biotech

Biotech Is Being Transformed by AI and Defense Demand

The global biotech market exceeds $600 billion and is entering a new innovation cycle powered by the convergence of AI, synthetic biology, and government investment. AI-driven drug discovery is compressing development timelines from decades to years. Synthetic biology is enabling the programmable production of materials, fuels, and therapeutics. And defense agencies worldwide are investing billions in biotech capabilities with national security implications.

Three trends define the current biotech investment landscape. First, computational biology has matured: AI models can now predict protein structures, simulate molecular interactions, and identify drug candidates with accuracy that fundamentally changes the economics of drug development. Second, the dual-use opportunity is expanding as governments recognize that biological technologies have profound defense applications - from biosecurity to advanced diagnostics to performance-enhancing materials. Third, the infrastructure layer of biotech (lab automation, bioinformatics, data platforms) is attracting venture capital as the enabling technology for the entire sector.

The risk profile of biotech investing is changing. Companies that combine AI capabilities with biological expertise can de-risk development programs earlier, reach clinical or commercial milestones faster, and attract follow-on capital more efficiently than traditional biotech approaches.

Uhlig Capital's biotech exposure includes Portal Biotechnologies ($8M+ DARPA contract), Seqera Labs (bioinformatics infrastructure, $26M Series B), and broader biotech access through Undeterred Capital - a fund manager that publishes deep-dive research across the biotech landscape and whose thesis-driven approach identified Portal Bio before its DARPA validation.